Qais Hamarsha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qais Hamarsha has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Hassan Kawtharany
Evidence-Based Practice and Impact Center, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
4 shared publications - Muayad Azzam
Evidence-Based Practice and Impact Center, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
4 shared publications - Reem A. Mustafa
University of Kansas Medical Center, Kansas City, Kansas, United States
4 shared publications - Jana Khawandi
23Department of Internal Medicine, Evidence-Based Practice and Impact Center, University of Kansas Medical Center, Kansas City, KS
3 shared publications - Ali Choaib
23Department of Internal Medicine, Evidence-Based Practice and Impact Center, University of Kansas Medical Center, Kansas City, KS
2 shared publications Aseel Alkhader
Evidence-Based Practice and Impact Center, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
2 shared publications
Latest Publications
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7725-7738
Diagnostic accuracy of fat pad sampling and bone marrow biopsy for AL amyloidosis: a systematic review and meta-analysis
In this systematic review, we aimed to assess the diagnostic test accuracy of abdominal fat pad sampling and bone marrow biopsy for immunoglobulin light-chain amyloidosis using organ biopsy as the reference standard. We searched the literature using PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) databases from inception to March 2024. We used Quality Assessment of Diagnostic Accuracy Studies-2 to assess the risk of bias and the Grading of Recommendations Assessment, Development, and Evaluation approach to assess the certainty of evidence. After deduplication, 29 237 records were screened and 31 studies were included. Among the studies, 25 (n = 4649) reported on fat pad sampling, with a pooled sensitivity of 0.77 (95% confidence interval, 0.72-0.81), whereas 20 (n = 2771) reported on bone marrow biopsy, with a pooled sensitivity of 0.55 (0.46-0.63). All studies enrolled patients with confirmed disease; specificity was not reported in the included studies. Fat pad aspiration (15 studies, n = 1590) and surgical or punch biopsy (4 studies, n = 222) had similar sensitivities of 0.80 (0.76-0.83) and 0.77 (0.61-0.88), respectively. In a single study (n = 612), performing both tests together yielded a sensitivity of 0.89. Certainty of evidence was judged to be moderate for fat pad sampling and low for bone marrow biopsy.
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7725-7738
Diagnostic accuracy of fat pad sampling and bone marrow biopsy for AL amyloidosis: a systematic review and meta-analysis
In this systematic review, we aimed to assess the diagnostic test accuracy of abdominal fat pad sampling and bone marrow biopsy for immunoglobulin light-chain amyloidosis using organ biopsy as the reference standard. We searched the literature using PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) databases from inception to March 2024. We used Quality Assessment of Diagnostic Accuracy Studies-2 to assess the risk of bias and the Grading of Recommendations Assessment, Development, and Evaluation approach to assess the certainty of evidence. After deduplication, 29 237 records were screened and 31 studies were included. Among the studies, 25 (n = 4649) reported on fat pad sampling, with a pooled sensitivity of 0.77 (95% confidence interval, 0.72-0.81), whereas 20 (n = 2771) reported on bone marrow biopsy, with a pooled sensitivity of 0.55 (0.46-0.63). All studies enrolled patients with confirmed disease; specificity was not reported in the included studies. Fat pad aspiration (15 studies, n = 1590) and surgical or punch biopsy (4 studies, n = 222) had similar sensitivities of 0.80 (0.76-0.83) and 0.77 (0.61-0.88), respectively. In a single study (n = 612), performing both tests together yielded a sensitivity of 0.89. Certainty of evidence was judged to be moderate for fat pad sampling and low for bone marrow biopsy.
- 30 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7353-7374
American Society of Hematology 2026 guidelines for diagnosis of iron deficiency
Background: Iron deficiency is the most common micronutrient deficiency and, when untreated, progresses to anemia. Existing guidance on the diagnostic criteria for iron deficiency is limited and not evidence based. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the diagnosis of iron deficiency, taking a global perspective in all settings. Methods: ASH established a multidisciplinary guideline panel that included 1 patient representative and was balanced to minimize potential bias from conflicts of interest. The University of Kansas Health System supported the guideline-development process, including performing systematic evidence reviews on the prevalence of iron deficiency across populations and studies to inform diagnostic thresholds up to July 2025. The panel prioritized clinical questions according to clinical impact and high-risk populations. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subsequently open for public comment. Results: The panel agreed on 5 recommendations. Conclusions: Key recommendations of these guidelines include serum ferritin thresholds for specific populations, with the goal to prioritize the diagnosis of iron deficiency, irrespective of the presence of anemia, remarks for considerations of other diagnostic thresholds, and guidance on the diagnosis of iron deficiency in persons with inflammation. Gaps in the literature and research priorities were also identified.
- 30 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7353-7374
American Society of Hematology 2026 guidelines for diagnosis of iron deficiency
Background: Iron deficiency is the most common micronutrient deficiency and, when untreated, progresses to anemia. Existing guidance on the diagnostic criteria for iron deficiency is limited and not evidence based. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the diagnosis of iron deficiency, taking a global perspective in all settings. Methods: ASH established a multidisciplinary guideline panel that included 1 patient representative and was balanced to minimize potential bias from conflicts of interest. The University of Kansas Health System supported the guideline-development process, including performing systematic evidence reviews on the prevalence of iron deficiency across populations and studies to inform diagnostic thresholds up to July 2025. The panel prioritized clinical questions according to clinical impact and high-risk populations. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subsequently open for public comment. Results: The panel agreed on 5 recommendations. Conclusions: Key recommendations of these guidelines include serum ferritin thresholds for specific populations, with the goal to prioritize the diagnosis of iron deficiency, irrespective of the presence of anemia, remarks for considerations of other diagnostic thresholds, and guidance on the diagnosis of iron deficiency in persons with inflammation. Gaps in the literature and research priorities were also identified.
- Open Access
- 25 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 5991-5994
Secondary Anticoagulation Prophylaxis for Children with Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis
- 25 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 5991-5994
Open AccessSecondary Anticoagulation Prophylaxis for Children with Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis
- Top Cited PapersOpen Access
- 12 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (12) , 4303-4333
ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism
Background: Venous thromboembolism (VTE) is a significant cause of morbidity in children, particularly among hospitalized patients and those with chronic medical conditions. There is a lack of consensus on anticoagulant prophylaxis strategies. Objective: These evidence-based guidelines from the American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) are intended to support patients and health care professionals in decisions about anticoagulant prophylaxis for pediatric VTE prevention. Methods: ASH formed a multidisciplinary guideline panel that included 1 patient representative. The University of Kansas Health System supported the guideline development process, including systematic evidence reviews up to April 2025. Clinical questions and outcomes were prioritized according to their importance for clinicians and patients. The panel used the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach to assess certainty in the evidence and make recommendations. Results: The panel agreed on 12 recommendations. For pediatric patients with solid cancer, who have experienced trauma, or who are critically ill, the panel issued conditional recommendations suggesting no anticoagulant prophylaxis. For pediatric patients with antiphospholipid antibody syndrome, or those on long-term total parenteral nutrition, the panel issued conditional recommendations suggesting the use of anticoagulant prophylaxis. Other pediatric subgroups addressed included patients with acute lymphoblastic leukemia or lymphoma, surgical and hospitalized patients, and those with a central venous access device. Conclusions: High-quality data on anticoagulant prophylaxis for pediatric VTE prevention are scarce. Key research priorities include the development and validation of subgroups-specific VTE risk assessment models, and evaluation of the safety and efficacy of risk-stratified anticoagulant prophylaxis strategies across different pediatric subgroups.
- 12 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (12) , 4303-4333
Top Cited PapersOpen AccessASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism
Background: Venous thromboembolism (VTE) is a significant cause of morbidity in children, particularly among hospitalized patients and those with chronic medical conditions. There is a lack of consensus on anticoagulant prophylaxis strategies. Objective: These evidence-based guidelines from the American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) are intended to support patients and health care professionals in decisions about anticoagulant prophylaxis for pediatric VTE prevention. Methods: ASH formed a multidisciplinary guideline panel that included 1 patient representative. The University of Kansas Health System supported the guideline development process, including systematic evidence reviews up to April 2025. Clinical questions and outcomes were prioritized according to their importance for clinicians and patients. The panel used the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach to assess certainty in the evidence and make recommendations. Results: The panel agreed on 12 recommendations. For pediatric patients with solid cancer, who have experienced trauma, or who are critically ill, the panel issued conditional recommendations suggesting no anticoagulant prophylaxis. For pediatric patients with antiphospholipid antibody syndrome, or those on long-term total parenteral nutrition, the panel issued conditional recommendations suggesting the use of anticoagulant prophylaxis. Other pediatric subgroups addressed included patients with acute lymphoblastic leukemia or lymphoma, surgical and hospitalized patients, and those with a central venous access device. Conclusions: High-quality data on anticoagulant prophylaxis for pediatric VTE prevention are scarce. Key research priorities include the development and validation of subgroups-specific VTE risk assessment models, and evaluation of the safety and efficacy of risk-stratified anticoagulant prophylaxis strategies across different pediatric subgroups.